Key Finding:
DLL3-H expression was associated with “undruggable” genomic features, and may serve as a target for for neuroendocrine neoplasm patients with functional loss of tumor suppressors TP53 and RB1, as well as increased activity of KRAS, WNT and MYC signaling.